These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33418337)

  • 41. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice.
    Caine EA; Fuchs J; Das SC; Partidos CD; Osorio JE
    Viruses; 2015 Nov; 7(11):5919-32. PubMed ID: 26593938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps.
    Ku Z; Ye X; Huang X; Cai Y; Liu Q; Li Y; Su Z; Huang Z
    PLoS One; 2013; 8(2):e57601. PubMed ID: 23451250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EV71 vaccines: a first step towards multivalent hand, foot and mouth disease vaccines.
    Klein MH
    Expert Rev Vaccines; 2015 Mar; 14(3):337-40. PubMed ID: 25536888
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice.
    Yee PTI; Tan SH; Ong KC; Tan KO; Wong KT; Hassan SS; Poh CL
    Sci Rep; 2019 Mar; 9(1):4805. PubMed ID: 30886246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
    Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
    Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Seroepidemiology of Coxsackievirus A10 infection in infants and children: A prospective cohort study in Jiangsu, China.
    Fu Y; Sun SY; Mao QY; Bian LL; Wu X; Zhu FC; Jiang CL; Gao F; Liang ZL
    J Infect; 2018 Aug; 77(2):158-164. PubMed ID: 29746947
    [No Abstract]   [Full Text] [Related]  

  • 47. Development of a high-growth enterovirus 71 vaccine candidate inducing cross-reactive neutralizing antibody responses.
    Chia MY; Chung WY; Wang CH; Chang WH; Lee MS
    Vaccine; 2018 Feb; 36(9):1167-1173. PubMed ID: 29398272
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Novel Attenuated Enterovirus A71 Mutant with VP1-V238A,K244R Exhibits Reduced Efficiency of Cell Entry/Exit and Augmented Binding Affinity to Sulfated Glycans.
    Meng T; Wong SM; Chua KB
    J Virol; 2021 Oct; 95(22):e0105521. PubMed ID: 34468173
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inactivated enterovirus 71 with poly-γ-glutamic acid/Chitosan nano particles (PC NPs) induces high cellular and humoral immune responses in BALB/c mice.
    Pathinayake PS; Gayan Chathuranga WA; Lee HC; Chowdhury MYE; Sung MH; Lee JS; Kim CJ
    Arch Virol; 2018 Aug; 163(8):2073-2083. PubMed ID: 29619599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation.
    Mao Q; Wang Y; Gao R; Shao J; Yao X; Lang S; Wang C; Mao P; Liang Z; Wang J
    J Virol; 2012 Nov; 86(22):11967-76. PubMed ID: 22951825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparative study of multiple clinical enterovirus 71 isolates and evaluation of cross protection of inactivated vaccine strain FY-23 K-B in vitro.
    Yang T; Li H; Yue L; Song X; Xie T; Ma S; Meng H; Zhang Y; He X; Long R; Yang R; Luo F; Xie Z; Li Q
    Virol J; 2017 Oct; 14(1):206. PubMed ID: 29073897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adaptation of enterovirus 71 to adult interferon deficient mice.
    Caine EA; Partidos CD; Santangelo JD; Osorio JE
    PLoS One; 2013; 8(3):e59501. PubMed ID: 23527208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases.
    Liu CC; Chow YH; Chong P; Klein M
    Vaccine; 2014 Oct; 32(47):6177-82. PubMed ID: 25218294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.
    Yang L; Liu Y; Li S; Zhao H; Lin Q; Yu H; Huang X; Zheng Q; Cheng T; Xia N
    Vaccine; 2016 Nov; 34(48):5938-5945. PubMed ID: 27771182
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative pathogenicity of Coxsackievirus A16 circulating and noncirculating strains in vitro and in a neonatal mouse model.
    Huang L; Liu X; Li JL; Chang JL; Liu GC; Yu XF; Zhang WY
    Braz J Med Biol Res; 2015 May; 48(5):420-6. PubMed ID: 25831207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of a pseudovirus based assay for measuring neutralizing antibodies against coxsackievirus B5.
    Chen P; Wu X; Su Y; Hao X; Mao Q; Liang Z
    J Virol Methods; 2017 Aug; 246():21-26. PubMed ID: 28435072
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.
    Hankaniemi MM; Laitinen OH; Stone VM; Sioofy-Khojine A; Määttä JAE; Larsson PG; Marjomäki V; Hyöty H; Flodström-Tullberg M; Hytönen VP
    Vaccine; 2017 Jun; 35(30):3718-3725. PubMed ID: 28579231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.
    Lin CW; Liu CC; Lu TC; Liu SJ; Chow YH; Chong P; Huang MH
    Biomed Res Int; 2014; 2014():670506. PubMed ID: 25006583
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system.
    Liu CC; Guo MS; Lin FH; Hsiao KN; Chang KH; Chou AH; Wang YC; Chen YC; Yang CS; Chong PC
    PLoS One; 2011; 6(5):e20005. PubMed ID: 21603631
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is a multivalent hand, foot, and mouth disease vaccine feasible?
    Klein M; Chong P
    Hum Vaccin Immunother; 2015; 11(11):2688-704. PubMed ID: 26009802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.